FedEx Corp. FDX – Options Review
Despite having signaled our options idea FDX on Tuesday morning, it was a postmarket drop, thus, leading into yesterday’s session, the earnings were still untraded upon. We reminded readers yesterday morning to look out for what we expected to be a solid performance, and we were not wrong.
Our sole target, the FDX Weekly $237.50 Calls ran from a low of 7.95 all the way up to 19.00 for us, which mean our idea has been good for a gain of up to 139% to this point.
With the markets flailing and looking to be set up for a lackluster day, we are going to open things up today and track a few sets of bearish options ideas for the SPY, AAPL, and NKE chains.
SPY Weekly $335-333 Puts
AAPL Weekly $111.25-108.75 Puts
NKE Weekly $118-117 Puts
PPCB, VNUE, TSOI, CLHI, HENC, CETY
Nkarta, Inc. NKTX – Form-4 Alert
We took notice of an interesting new IPO this morning in NKTX. Typically we would be more interested in stocks with a long history of data to look at, but in this case a notable name is buying up shares. Mega-laboratory GlaxoSmithKline purchased a noteworthy $15M chunk of NKTX, and the newly issued stock has been in a freefall looking for support.
In our experience, we see a lot of IPO’s that sell off hard directly after their initial offering just like this one. It’s when they establish a firm bottom that the buying opportunity is at its greatest, so we are definitely going to want to keep a close watch over NKTX for that to occur. There may be a solid gain opportunity on the horizon here that we won’t want to miss.
Virgin Galactic Holdings Inc. SPCE
We highlighted some calls in SPCE last week and met with great success, to the tune of several multi-bag gain opportunites. It has continued to run this week, and so far we’ve seen a 39% move in the stock alone from 19.07-23.53.
We are interested in selecting another range of calls to monitor with SPCE faring so well, so we’re going to place the SPCE $25.50-26.50 Calls on watch for the remainder of the week.
GeoVax Labs, Inc. GOVX
We tagged GOVX in our extended watchlist on Tuesday, and this stock has made an absolutely eye-popping move.
From its low of .62 on Tuesday, GOVX hit 1.75 yesterday, marking a total two-day upswing of 182% We’ll continue to keep an eye peeled for more activity in this highly volatile play.
KMB Weekly $145-148 Calls
DHR 08/21 $200-210 Calls
MSTO, WNDW, VYST, TSOI, LTUM
The X-Change Corporation XCHC
Yesterday, following our alert on XCHC, the stock opened up at .0699, and subsequently hit a high of .079 (+13%) where it ran into some resistance. It then pulled back to .056 before running back to its opening price of .0699 (+25%). We’d call that a solid first day, with total gains of up to 38% presenting themselves.
In press release published yesterday, the company announced its plans to roll out its Phytiva products in S. California. The second announcement of its kind in the last week, we can see that XCHC is rigorously pursuing its quest to expand its recently acquired line.
DALLAS, Jan. 28, 2013 /PRNewswire via COMTEX/ — X-Change Corp. (NASDAQ OTC: XCHC), a U.S. boutique company whose niche is extract-based Cosmeceutical and Nutraceuticals solutions through its Phytiva brand product line, announced today that it has been in discussions with California-based cannabis businesses for plans of a full rollout of Phytiva products to consumers in Southern California.The California legal cannabis market is estimated at $12 -$18 billion in total economic activity, supporting 60,000 to 110,000 jobs and $2.5 to $3.5 billion in legal, taxable wages. The cannabis industry is a much needed windfall for the State of California which is in economic distress. Further, the industry would generate additional income and business taxes for the state. California is one of the leading states for Medical Cannabis since first legalizing in mid 1990’s.
These inquiries came from conservative, well-managed firms that participate in full legal compliance through their dispensary licenses. They have physical locations in place that will allow X-Change Corporation to market its full line of Phytiva products.
You may have missed yesterday’s link to our short video presentation of XCHC, so click here and take a look.
For more information, visit: http://www.phytiva.com
Therapeutic Solutions International, Inc. TSOI
A few weeks ago, we noticed TSOI coming off its 52-week low of .01. It was January 14th and 15th when we included it in our extended watchlist, and it was trading as low as .0151. Yesterday the stock managed to close at the high of day of .045, breaching its 20, 50 and 100DMA’s. That move represents a possible gain of 198% from our first mention just two weeks prior.
We would like to see support hold at .04, above the moving averages going forward in order for us to remain bullish on TSOI.
Keryx Biopharmaceuticals, Inc. KERX
Speaking of watchlist plays that have made their mark, KERX appeared in our extended watchlist on January 23rd. We’ve since watched it run from a low of 3.46, and we are now observing pre- market trading at 7.03, a gain of 103%
MYRY, IFLM, MILV, PLXT